These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34599393)

  • 21. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of pricing strategy on the costs of oral anti-cancer drugs.
    Truong J; Chan KKW; Mai H; Chambers A; Sabharwal M; Trudeau ME; Cheung MC
    Cancer Med; 2019 Jul; 8(8):3770-3781. PubMed ID: 31132223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug rebates in Medicare Part D: Excess patient costs in the case of hepatitis C treatments.
    Arambadjis Y; Butler M; Huckfeldt P; Schondelmeyer S
    Res Social Adm Pharm; 2020 Sep; 16(9):1290-1293. PubMed ID: 31147206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. German Pharmaceutical Pricing: Lessons for the United States.
    Rodwin MA; Gerke S
    Int J Health Serv; 2022 Jan; 52(1):146-158. PubMed ID: 34668806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High prices for generics in Australia - more competition might help.
    Bulfone L
    Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.
    Dusetzina SB; Conti RM; Yu NL; Bach PB
    JAMA Intern Med; 2017 Aug; 177(8):1185-1188. PubMed ID: 28558108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
    Hernandez I; San-Juan-Rodriguez A; Good CB; Gellad WF
    JAMA; 2020 Mar; 323(9):854-862. PubMed ID: 32125403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
    Blankart CR; Stargardt T; Schreyögg J
    Pharmacoeconomics; 2011 Jan; 29(1):63-82. PubMed ID: 21073206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Limited options to manage specialty drug spending.
    Tu HT; Samuel DR
    Res Brief; 2012 Apr; (22):1-13. PubMed ID: 23155549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of international coverage and pricing strategies for personalized medicine and orphan drugs.
    Degtiar I
    Health Policy; 2017 Dec; 121(12):1240-1248. PubMed ID: 29033060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness and pricing of caffeine.
    Zupancic JAF
    Semin Fetal Neonatal Med; 2020 Dec; 25(6):101179. PubMed ID: 33277220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study.
    Lin JK; Moran AE; Bibbins-Domingo K; Falase B; Pedroza Tobias A; Mandke CN; Kazi DS
    Lancet Glob Health; 2019 Oct; 7(10):e1346-e1358. PubMed ID: 31477544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do interventions that address patient cost-sharing improve adherence to prescription drugs? A systematic review of recently published studies.
    Sensharma A; Yabroff KR
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):263-277. PubMed ID: 30628493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of orphan drugs prices in France: a regression analysis.
    Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
    Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.